The role of b-type natriuretic peptide in heart failure management
MetadataShow full item record
Summary. Heart failure is a complex clinical syndrome that manifests itself with signs and symptoms which are neither sensitive nor specific for the diagnosis of heart failure. Natriuretic peptides and in particular b-type natriuretic peptide (and nt-proBNP) are widely used in clinical practice around the world as a maker of heart failure. BNP is primarly released from the left ventricle in response to pressure and volume overload. The strongest evidence for the use of BNP is to rule in or rule out heart failure as cause of breathlessness in people who present to the emergency room. There is enthusiasm for use of BNP as a market of heart failure severity as well as a predictor of outcomes in people with heart failure and trials are ongoing. Nesiritide, a recombinant form of BNP is currently being tested as a possible treatment in people with acutely decompensated heart failure.
The link to the journal’s home page is: http://www.australiancriticalcare.com/ Copyright © 2009 Elsevier B.V. All rights reserved
Showing items related by title, author, creator and subject.
Angiotensin receptor neprilysin inhibitor LCZ696: Pharmacology, pharmacokinetics and clinical developmentHua, Y.; Wang, I.; Liu, B.; Kelly, D.; Reid, Christopher; Liew, D.; Zhou, Y.; Wang, B. (2017)© 2017 Future Medicine Ltd.Heart failure still has a significant disease burden with poor outcomes worldwide despite advances in therapy. The standard therapies have been focused on blockade of renin-angiotensin-aldosterone ...
SCReening Evaluation of the Evolution of New Heart Failure Study (SCREEN-HF): early detection of chronic heart failure in the workplaceBoffa, U.; McGrady, M.; Reid, Christopher; Shiel, L.; Wolfe, R.; Liew, D.; Campbell, D.; Stewart, S.; Krum, H. (2016)Objective: The aim of the present study was to determine whether asymptomatic heart failure (HF) in the workplace is subject to the health worker effect, making screening using conventional risk factors combined with a ...
Most individuals with treated blood pressures above target receive only one or two antihypertensive drug classesCampbell, D.; Mcgrady, M.; Prior, D.; Coller, J.; Boffa, U.; Shiel, L.; Liew, D.; Wolfe, R.; Stewart, S.; Reid, Christopher; Krum, H. (2013)Background: A significant proportion of individuals taking antihypertensive therapies fail to achieve blood pressures <140/90mmHg. In order to develop strategies for improved treatment of blood pressure, we examined the ...